Major depressive disorder treatment market to grow to $9.7 billion by end 2023, after downturn until 2017

New research forecasts that the therapeutics market for major depressive disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products.

According to a new report from research and consulting firm GlobalData, the MDD treatment market achieved sales of around $9.3 billion in 2013 across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a compound annual growth rate (CAGR) of 0.39%.

However, GlobalData forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly’s Cymbalta (duloxetine), Otsuka Pharmaceutical/Bristol-Myers Squibb’ Abilify (aripiprazole) and AstraZeneca’s Seroquel XR (quetiapine).